2022-01-24
ViewReleaseInStandardHtml

Interview and company presentation in collaboration with Uddaaktier

CEO Anna Eriksrud presented NeoDynamics and answered questions about the business in an interview in collaboration with Uddaaktier. The interview can be accessed through the following link (Uddaaktier's YouTube channel): ://youtu.be/bO3IvZt5fVY

Among the topics discussed in the interview were:

The company’s goals and strategies

NeoDynamics is a medtech company focused on improving the diagnosis and treatment of cancer. The company has developed an innovative biopsy system, NeoNavia®. NeoDynamics’ vision is that the pulse technology becomes the new standard for all ultrasound-guided breast cancer biopsies, improve precision and reliability, thereby contributing to the correct diagnosis and individualized treatment without delay for each individual breast cancer patient. The launch of NeoNavia has begun in the UK, Germany and Sweden. Application for registration in the United States is being prepared.

NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

 

Market

In a first step, NeoDynamics focuses on breast cancer. At least 6 million biopsies are performed annually to diagnose suspected breast cancer, in a growing market with an estimated value of 725 million dollars 2020. Extended screening programs and new screening techniques enable more and more tumors to be detected earlier. New treatments increase the need for biopsies to establish a diagnosis, but also to monitor their effect.

 

For further information, please visit the company’s website or contact:

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

 

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.